'Magic Drug' Reduces Risk of Death by 44% in Lung Cancer Trial

(MedPage Today) -- A next-generation KRAS G12C inhibitor significantly improved survival outcomes versus first-generation drugs for previously treated advanced or metastatic non-small cell lung cancer, a phase III trial showed. Median progression...